Harbin Pollution Case Shows Increasing Environmental Scrutiny In China's Pharmaceutical Industry
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - When China's state-run television uncovered dangerous levels of pollution at a pharmaceutical plant in the Northern Chinese province of Harbin last week, a spotlight was thrown on polluting practices within the country's pharmaceuticals industry. Now, as authorities move to improve the enforcement of existing regulations, it is likely that more companies will be forced to clean up their act
You may also be interested in...
China’s Environmental Regs Put More Pressure On Pharma
As part of China’s five-year plan, environmental restrictions will increasingly get more attention, but punishments for lax companies will likely be tougher in urban areas where public awareness is greater.
U.S. FDA Warning Letter To Sichuan Pharma Only Tip Of The Iceberg For China State-Owned Company
WASHINGTON and SHANGHAI - U.S. FDA issued Sichuan Pharmaceutical Co., Ltd. a warning letter Sept. 9 for significant deviations from current good manufacturing practices in the manufacture of active pharmaceutical ingredients. The warning letter adds more woes to the troubled China state-owned enterprise, and the Chengdu government is looking for a basement price to unload the company
U.S. FDA Warning Letter To Sichuan Pharma Only Tip Of The Iceberg For China State-Owned Company
WASHINGTON and SHANGHAI - U.S. FDA issued Sichuan Pharmaceutical Co., Ltd. a warning letter Sept. 9 for significant deviations from current good manufacturing practices in the manufacture of active pharmaceutical ingredients. The warning letter adds more woes to the troubled China state-owned enterprise, and the Chengdu government is looking for a basement price to unload the company